PO-101 Relation between PSA level, its dynamics and performance of 18F-choline PET-CT in recurrent prostate cancer

• Published in: ESMO open 2018-07, Vol.3 (Suppl 2), p.A265-A265
• Main Authors: Siminiak, N, Wojciechowska, K, Miechowicz, I, Cegla, P, O’Shea-Otwiaska, A, Cholewinski, W, Ruchala, M, Czepczynski, R
• Format: Article
• Language: English
• ISSN: 2059-7029; 2059-7029
• DOI: 10.1136/esmoopen-2018-EACR25.627

IntroductionPET-CT using 18F-choline is widely used in diagnosis of prostate cancer local recurrence and metastases, whereas Prostate Specific Antigen (PSA) measurement is routinely used for biochemical monitoring. The purpose of our study was to evaluate performance of PET-CT with 18F-choline in relation to the PSA level or its change in time, in patients with biochemically diagnosed recurrent prostate cancer.Material and methods263 consecutive prostate cancer patients with elevation of PSA after treatment were included into the study. PSA values were evaluated at the time of PET scan (not more than 30 days before) and the PSA level change (ΔPSA) was calculated as a per month difference between two recent measurements. PET-CT was performed using Discovery IQ scanner (GE Healthcare ), 3 and 20 min after injection of 18F-choline (3 MBq/kg). Data are shown as median values (quartiles).Results and discussionsIn 164 patients, in whom PET-CT scan was positive and has shown local recurrence or metastases both the PSA level [5,85(2,09;17,37)] ng/ml and ΔPSA [0,54 (0,06;2,00)] ng/ml/month were significantly (p